Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
| Data(s) |
22/03/2014
|
|---|---|
| Resumo |
Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease. |
| Formato |
application/pdf |
| Identificador | |
| Idioma(s) |
eng |
| Direitos |
info:eu-repo/semantics/restrictedAccess |
| Fonte |
Cuzick , J , Sestak , I , Forbes , J F , Dowsett , M , Knox , J , Cawthorn , S , Saunders , C , Roche , N , Mansel , R E , von Minckwitz , G , Bonanni , B , Palva , T , Howell , A , IBIS-II investigators & McIntosh , S 2014 , ' Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial ' Lancet , vol 383 , pp. 1041-8 . DOI: 10.1016/S0140-6736(13)62292-8 |
| Palavras-Chave | #Adult #Aged #Antineoplastic Agents, Hormonal #Aromatase Inhibitors #Breast Neoplasms #Carcinoma, Ductal, Breast #Carcinoma, Intraductal, Noninfiltrating #Carcinoma, Lobular #Double-Blind Method #Female #Humans #Longitudinal Studies #Middle Aged #Nitriles #Postmenopause #Proportional Hazards Models #Risk Factors #Treatment Outcome #Triazoles |
| Tipo |
article |
